These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Oligometastatic recurrent prostate cancer detects by fluorine-18-choline positron emission tomography/computed tomography in patients with prostate-specific antigen levels of up to 5 ng/ml. Evangelista L, Cuppari L, Guttilla A, Gardi M, Agostini A, Ruggera L, Basso U, Saladini G. Nucl Med Commun; 2018 Mar; 39(3):260-267. PubMed ID: 29381584 [Abstract] [Full Text] [Related]
5. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. Castellucci P, Fuccio C, Nanni C, Santi I, Rizzello A, Lodi F, Franceschelli A, Martorana G, Manferrari F, Fanti S. J Nucl Med; 2009 Sep; 50(9):1394-400. PubMed ID: 19690023 [Abstract] [Full Text] [Related]
7. PET/CT with (18)F-choline after radical prostatectomy in patients with PSA ≤2 ng/ml. Can PSA velocity and PSA doubling time help in patient selection? Chiaravalloti A, Di Biagio D, Tavolozza M, Calabria F, Schillaci O. Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1418-24. PubMed ID: 26791373 [Abstract] [Full Text] [Related]
9. Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy? Castellucci P, Ceci F, Graziani T, Schiavina R, Brunocilla E, Mazzarotto R, Pettinato C, Celli M, Lodi F, Fanti S. J Nucl Med; 2014 Sep; 55(9):1424-9. PubMed ID: 24935990 [Abstract] [Full Text] [Related]
12. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics. Beheshti M, Haim S, Zakavi R, Steinmair M, Waldenberger P, Kunit T, Nader M, Langsteger W, Loidl W. J Nucl Med; 2013 Jun; 54(6):833-40. PubMed ID: 23559588 [Abstract] [Full Text] [Related]
13. A pilot study of the utility of choline PET-CT in prostate cancer biochemical relapse following radical prostatectomy. Tan H, Joseph D, Loh NK, McCarthy M, Leong E, Siew T, Segard T, Morandeau L, Trevenen M, Francis RJ. J Med Imaging Radiat Oncol; 2016 Jun; 60(3):374-81. PubMed ID: 27094471 [Abstract] [Full Text] [Related]
14. Dual-phase (18)F-fluorocholine PET/CT to detect locoregional recurrence of prostate cancer: comparison between each time point of imaging and a summation scan. Tong AK, Zhang ZX, Zaheer S, Yan XS. Clin Imaging; 2016 Jun; 40(3):486-91. PubMed ID: 27133692 [Abstract] [Full Text] [Related]
15. Diagnostic utility and therapeutic impact of PET/CT [18F]F-Fluoromethylcholine -Choline in the biochemical recurrence of prostate cancer. Sánchez N, Valduvieco I, Ribal MJ, Campos F, Casas F, Nicolau C, Salvador R, Mellado B, Jorcano S, Fuster D, Paredes P. Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020 Jun; 39(5):284-291. PubMed ID: 32467000 [Abstract] [Full Text] [Related]
18. Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml? Castellucci P, Fuccio C, Rubello D, Schiavina R, Santi I, Nanni C, Allegri V, Montini GC, Ambrosini V, Boschi S, Martorana G, Marzola MC, Fanti S. Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):55-63. PubMed ID: 20848281 [Abstract] [Full Text] [Related]
19. Role of 18F-choline PET/CT in biochemically relapsed prostate cancer after radical prostatectomy: correlation with trigger PSA, PSA velocity, PSA doubling time, and metastatic distribution. Marzola MC, Chondrogiannis S, Ferretti A, Grassetto G, Rampin L, Massaro A, Castellucci P, Picchio M, Al-Nahhas A, Colletti PM, Marcolongo A, Rubello D. Clin Nucl Med; 2013 Jan; 38(1):e26-32. PubMed ID: 23242060 [Abstract] [Full Text] [Related]